FDA Determines Regulatory Review Period for OJJAARA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of OJJAARA, a human drug product, following submissions to the U.S. Patent and Trademark Office (USPTO).